HEALTHY RETURNS: PROGNOSIS FOR RECOVERY

On February 9, CNBC’s Healthy Returns spotlight will update attendees with up-to-the minute information on the rollout of Covid-19 vaccines, for investors, policy makers and business leaders. As new vaccines continue to be approved, we’ll check in on the largest and most complicated mass vaccination program in history, how government and the private sector are working together, bringing an end to this pandemic. Plus – treating the mental health crisis brought about by Covid-19, the long lasting impact on people, business and the economy.

Featuring keynote and panel interviews, plus concurrent sessions, this event stands squarely at the intersection of the pandemic, economics and business to give critical information to move forward.

WHO SHOULD ATTEND: Health care investors, VCs, C-Suite executives from the biotech, pharma, health care and life sciences industries, health care IT BDMs.

COMING UP: Healthy Returns Summit – REGISTER

PAST EVENTS: 2020 Livestream | 2020 Summit | 2019 | 2018

Watch our 2020 Event Highlights

Visit cnbc.com/healthy-returns to find in-depth coverage from the CNBC team about health care innovation.

Subscribe to our Healthy Returns newsletter for exclusive insights on the biggest health care news from our reporters, delivered straight to your inbox every Friday.

SPEAKERS

Alex
Gorsky

Johnson & Johnson

Alex Gorsky is Chairman of the Board and Chief Executive Officer of Johnson & Johnson and Chairman of the Executive Committee.

Alex Gorsky

Alex Gorsky is Chairman of the Board and Chief Executive Officer of Johnson & Johnson and Chairman of the Executive Committee, the Company’s senior leadership team. Alex is the seventh person to serve as Chairman and CEO of Johnson & Johnson since it became a publicly traded company in 1944.

Alex began his Johnson & Johnson career as a sales representative with Janssen Pharmaceutica in 1988. Over the next 15 years, he advanced through positions of increasing responsibility in sales, marketing and management including assignments in the U.S., Europe, Africa and the Middle East. He progressed through many management posts at J&J, culminating in being named Chief Executive Officer on April 26, 2012 and Chairman of the Board on December 28, 2012.

Under Alex Gorsky’s leadership, Johnson & Johnson continues in its 132nd year to be one of the world’s exceptional corporations. The company was given the #1 ranking on Barron’s Magazine’s 2016 list of the “World’s Most Admired Companies,” and is currently the number one Pharmaceutical company on Fortune Magazine’s list of the “World’s Most Respected Companies.

A longtime advocate of Diversity Inclusion and Veteran’s issues, Alex has been named one of the “100 Most Inspiring Leaders” by Pharma Voice. Most recently, in December of 2017, Alex received the Ripple of Hope Award from the Robert F. Kennedy Human Rights Foundation. And for the past three years, Alex has been on the list of the Highest Rated CEOs on The Glassdoor Employees’ Choice Awards. He has also received the Jackie Robinson Award, Appeal of Conscience Award, the Joseph Wharton Leadership Award and the CADCA Humanitarian of the Year Award.

Alex is a member of the Board of Directors of IBM, the Wharton School of Business Board of Overseers and the Board of Directors of the Business Roundtable.

Alex holds a Bachelor of Science degree from the U.S. Military Academy at West Point, N.Y., and spent six years in the U.S. Army, finishing his military career with the rank of Captain. Alex earned a Master of Business Administration degree from The Wharton School of the University of Pennsylvania in 1996.

Rick
Gates

Walgreens

Rick Gates is SVP, Pharmacy and Healthcare of Walgreens.

Rick Gates

Rick Gates is senior vice president of pharmacy and healthcare at Walgreens, based in Deerfield Ill. He is responsible for commercial development and sales, contracting, pharma development, pharmacy supply chain, and clinical programs and alliances.
Before then he was group vice president of pharmacy where he led the strategic development, alignment and delivery of pharmacy-led health and wellness programs. He has served in roles of increasing responsibility since joining Walgreens in 1995 after graduation from pharmacy school including leading Walgreens Western Pharmacy Operations and responsible for integrating Duane Reade stores into the Walgreens network.
Rick serves as a board member with the National Association of Chain Drug Stores (NACDS) Foundation, University of Iowa College of Pharmacy Leadership Board, AllianceRx and Pharmacy Quality Alliance (PQA).
Rick received a B.S. in pharmacy from the University of Iowa in Iowa City. He is an active member of the American Pharmacist Association, NCPDP, NASP and the University of Iowa Alumni Association.

Anita
Jenkins

Howard University Hospital

Anita Jenkins is Chief Executive Officer of Howard University Hospital.

Anita Jenkins

Anita Jenkins is the Chief Executive Officer at Howard University Hospital in Washington DC. As a key part of Howard’s partnership with Adventist Healthcare, Jenkins is leading the transformational three-year management services agreement with Adventist as Howard University Hospital continues to provide care to its surrounding community in a culturally focused environment. She will also be guiding Howard University Hospital through its new replacement hospital project with a focus on improving patient safety, patient quality, and patient outcomes.

In her over 20 years of healthcare experience and leadership, Jenkins developed expertise in hospital operations, healthcare management, and strategic planning. Prior to her role at Howard University Hospital, Anita Jenkins was president of Sycamore Medical Center near Dayton, Ohio. While there, she was responsible for daily operations of all clinical inpatient and outpatient services including nursing, rehabilitation, and patient relations.

Anita Jenkins’ approach to the business side of healthcare is informed by her days as a respiratory therapist at the University of Pittsburgh Medical Center where Jenkins gained first-hand experience in caring for patients with compassion. This background translates into her focus as Howard University Hospitals new CEO, working directly with staff and the DC community. Since assuming her role at Howard University Hospital at the onset of the COVID-19 pandemic, Jenkins has focused her efforts on understanding DC’s changing landscape, and how to best serve the DC area community.

Marc
Rogers

Okta

Marc Rogers is Executive Director, Cybersecurity at Okta.

Marc Rogers

Marc Rogers is VP of Cybersecurity at Okta. With a career that spans more than twenty years, he has been hacking since the 80’s and is now a white-hat hacker renowned for hacking things like Apple's TouchID and the Tesla Model S. Prior to Okta, Mr. Rogers served as the Head of Security for Cloudflare and spent a decade managing security for the UK operator, Vodafone. He's been a CISO in South Korea and has also co-founded a disruptive Bay Area startup. In his role as technical advisor on “Mr. Robot,” he helped create hacks for the show. He's also an organizer and the Head of Security for the world’s largest hacking conference: DEF CON. Most recently Mr Rogers helped found the CTI League, a multinational cybersecurity initiative combining industry professionals, government agencies and law enforcement from 80 different countries.

Alok
Kanojia

Healthy Gamer

Dr. Alok Kanojia is a Psychiatrist, and President and Co-founder of Healthy Gamer.

Alok Kanojia

Dr. Alok Kanojia, also known as “Dr. K”, is a Harvard-trained psychiatrist specializing in mental health for the internet generation, gamers and their families. He is the President and Cofounder of Healthy Gamer, a mental health platform that provides content, coaching, and community resources to help young people take control of their mental health and their lives.

Dr. K designs mental health solutions for young people by combining the best of evidence-based psychiatry, complementary and alternative medicine (CAM), and his own experiences as part of that internet generation to create a truly unique approach to mental health. When he’s off-duty, he’s probably watching Dota 2 or telling stories about dragons to his 2 daughters.

Kris
Joshi

Change Healthcare

Kris Joshi is EVP and President, Network Solutions of Change Healthcare.

Kris Joshi

Kris Joshi is executive vice president and president, Network Solutions, for Change Healthcare. Prior to joining Change Healthcare, Mr. Joshi was global vice president for healthcare product strategy for the Health Sciences global business unit at Oracle Corporation. He helped launch the Health Sciences business unit and successfully led two acquisitions for Oracle in Life Sciences. Before joining Oracle, Mr. Joshi served in senior strategy roles with IBM’s Global Sales and Distribution organization, and prior to IBM, Mr. Joshi was at McKinsey and Company, where he worked with Fortune 500 companies on strategy issues.
 
Mr. Joshi holds a B.S. in mathematics from the California Institute of Technology and a Ph.D. in physics from the Massachusetts Institute of Technology. He currently serves on the boards of the Personalized Medicine Coalition and the eHealth Initiative in Washington, DC.

Tim
Suther

Change Healthcare

Tim Suther is SVP and General Manager, Data Solutions of Change Healthcare.

Tim Suther

Tim Suther is senior vice president and general manager, Data Solutions for Change Healthcare. In this leadership role, he focuses on inspiring a better healthcare system through the effective and responsible use of data and analytics.

Mr. Suther’s career spans more than three decades of maximizing commercial and societal value through data, analytics and technology transformation. Previous roles included founder and entrepreneur (Suther Strategic LLC), managing director, Intelligent Solutions (JPMorgan Chase), chief marketing and strategy officer (Acxiom), senior vice president (Metavante), president (Protagona Worldwide), and a variety of roles at Unisys.

He is a member of the board of directors at Label Insight and at Commerce Signals, two companies focused on innovative uses of data. He is a member of the Loras College Board of Regents and a member of its Executive Committee. He was named an ExecRank Top CMO in 2012, a Social Media Marketing Top CMO on Twitter, a BlueFocus Marketing Nifty50 Men in Technology. He won the CMO Club Presidents Award in 2015.

Suther holds a degree in finance and marketing from Loras College.

Shibani
Joshi

Technology Journalist

Shibani Joshi is a Technology Journalist.

Shibani Joshi

Shibani Joshi is an experienced journalist who has covered business, technology and general news for global media outlets including ABC News, Fox News Channel, Yahoo! Finance and Huffington Post. She provides commentary on business, technology and lifestyle topics and hosts events for leading corporations.

Previously, Shibani anchored a daily markets show and had her own dedicated segment on TV called “Joshi on Tech” on the Fox Business Network in New York City. In her almost 6-year tenure, she evolved into the dedicated on-air tech reporter at both Fox News Channel and Fox Business Network.

Shibani also reported extensively live on the floor of the New York Stock Exchange, Nasdaq and NYMex exchanges, covering the 2008 market crash, historic interest rate cuts, record oil prices and the biggest point drop in Dow history (at the time).

Throughout her career, Shibani has interviewed large-cap tech CEOs and executives from companies including Apple, Qualcomm, Google, Sony and Ebay. She has also interviewed execs from Uber, Dropbox, Rent the Runway and Angie’s List in their early stages.

Her unique business perspective stems from real-world corporate experience and a distinguished business education. After double majoring in finance and accounting, she worked as an investment banking analyst at Morgan Stanley in New York City, where she focused on corporate finance and M&A projects.

Joshi later moved on to Disney/ABC Media Networks, where she was the firm’s Senior Manager of Digital Strategy. In 2014, she created ShibanionTech.com, a blog focused on stories at the intersection of lifestyle and technology.
Shibani teaches at the University of Oklahoma, sits on the Board of Advisors for the Price College of Business at the University of Oklahoma, and served as a Trustee to The Children’s School in La Jolla, California.

Shibani is a graduate of the University of Oklahoma and holds an MBA from The Harvard Business School. She currently lives in the Bay Area with her 3 children.

SPEAKERS

  • ALEX GORSKY

    CNBC Read Bio ⟶

    Kate Rooney

    Alex Gorsky is Chairman of the Board and Chief Executive Officer of Johnson & Johnson and Chairman of the Executive Committee, the Company’s senior leadership team. Alex is the seventh person to serve as Chairman and CEO of Johnson & Johnson since it became a publicly traded company in 1944.

    Alex began his Johnson & Johnson career as a sales representative with Janssen Pharmaceutica in 1988. Over the next 15 years, he advanced through positions of increasing responsibility in sales, marketing and management including assignments in the U.S., Europe, Africa and the Middle East. He progressed through many management posts at J&J, culminating in being named Chief Executive Officer on April 26, 2012 and Chairman of the Board on December 28, 2012.

    Under Alex Gorsky’s leadership, Johnson & Johnson continues in its 132nd year to be one of the world’s exceptional corporations. The company was given the #1 ranking on Barron’s Magazine’s 2016 list of the “World’s Most Admired Companies,” and is currently the number one Pharmaceutical company on Fortune Magazine’s list of the “World’s Most Respected Companies.

    A longtime advocate of Diversity Inclusion and Veteran’s issues, Alex has been named one of the “100 Most Inspiring Leaders” by Pharma Voice. Most recently, in December of 2017, Alex received the Ripple of Hope Award from the Robert F. Kennedy Human Rights Foundation. And for the past three years, Alex has been on the list of the Highest Rated CEOs on The Glassdoor Employees’ Choice Awards. He has also received the Jackie Robinson Award, Appeal of Conscience Award, the Joseph Wharton Leadership Award and the CADCA Humanitarian of the Year Award.

    Alex is a member of the Board of Directors of IBM, the Wharton School of Business Board of Overseers and the Board of Directors of the Business Roundtable.

    Alex holds a Bachelor of Science degree from the U.S. Military Academy at West Point, N.Y., and spent six years in the U.S. Army, finishing his military career with the rank of Captain. Alex earned a Master of Business Administration degree from The Wharton School of the University of Pennsylvania in 1996.

  • RICK GATES

    CNBC Read Bio ⟶

    Kate Rooney

    Rick Gates is senior vice president of pharmacy and healthcare at Walgreens, based in Deerfield Ill. He is responsible for commercial development and sales, contracting, pharma development, pharmacy supply chain, and clinical programs and alliances.
    Before then he was group vice president of pharmacy where he led the strategic development, alignment and delivery of pharmacy-led health and wellness programs. He has served in roles of increasing responsibility since joining Walgreens in 1995 after graduation from pharmacy school including leading Walgreens Western Pharmacy Operations and responsible for integrating Duane Reade stores into the Walgreens network.
    Rick serves as a board member with the National Association of Chain Drug Stores (NACDS) Foundation, University of Iowa College of Pharmacy Leadership Board, AllianceRx and Pharmacy Quality Alliance (PQA).
    Rick received a B.S. in pharmacy from the University of Iowa in Iowa City. He is an active member of the American Pharmacist Association, NCPDP, NASP and the University of Iowa Alumni Association.

  • ANITA JENKINS

    CNBC Read Bio ⟶

    Kate Rooney

    Anita Jenkins is the Chief Executive Officer at Howard University Hospital in Washington DC. As a key part of Howard’s partnership with Adventist Healthcare, Jenkins is leading the transformational three-year management services agreement with Adventist as Howard University Hospital continues to provide care to its surrounding community in a culturally focused environment. She will also be guiding Howard University Hospital through its new replacement hospital project with a focus on improving patient safety, patient quality, and patient outcomes.

    In her over 20 years of healthcare experience and leadership, Jenkins developed expertise in hospital operations, healthcare management, and strategic planning. Prior to her role at Howard University Hospital, Anita Jenkins was president of Sycamore Medical Center near Dayton, Ohio. While there, she was responsible for daily operations of all clinical inpatient and outpatient services including nursing, rehabilitation, and patient relations.

    Anita Jenkins’ approach to the business side of healthcare is informed by her days as a respiratory therapist at the University of Pittsburgh Medical Center where Jenkins gained first-hand experience in caring for patients with compassion. This background translates into her focus as Howard University Hospitals new CEO, working directly with staff and the DC community. Since assuming her role at Howard University Hospital at the onset of the COVID-19 pandemic, Jenkins has focused her efforts on understanding DC’s changing landscape, and how to best serve the DC area community.

  • MARC ROGERS

    CNBC Read Bio ⟶

    Kate Rooney

    Marc Rogers is VP of Cybersecurity at Okta. With a career that spans more than twenty years, he has been hacking since the 80’s and is now a white-hat hacker renowned for hacking things like Apple's TouchID and the Tesla Model S. Prior to Okta, Mr. Rogers served as the Head of Security for Cloudflare and spent a decade managing security for the UK operator, Vodafone. He's been a CISO in South Korea and has also co-founded a disruptive Bay Area startup. In his role as technical advisor on “Mr. Robot,” he helped create hacks for the show. He's also an organizer and the Head of Security for the world’s largest hacking conference: DEF CON. Most recently Mr Rogers helped found the CTI League, a multinational cybersecurity initiative combining industry professionals, government agencies and law enforcement from 80 different countries.

  • ALOK KANOJIA

    CNBC Read Bio ⟶

    Kate Rooney

    Dr. Alok Kanojia, also known as “Dr. K”, is a Harvard-trained psychiatrist specializing in mental health for the internet generation, gamers and their families. He is the President and Cofounder of Healthy Gamer, a mental health platform that provides content, coaching, and community resources to help young people take control of their mental health and their lives.

    Dr. K designs mental health solutions for young people by combining the best of evidence-based psychiatry, complementary and alternative medicine (CAM), and his own experiences as part of that internet generation to create a truly unique approach to mental health. When he’s off-duty, he’s probably watching Dota 2 or telling stories about dragons to his 2 daughters.

  • KRIS JOSHI

    CNBC Read Bio ⟶

    Kate Rooney

    Kris Joshi is executive vice president and president, Network Solutions, for Change Healthcare. Prior to joining Change Healthcare, Mr. Joshi was global vice president for healthcare product strategy for the Health Sciences global business unit at Oracle Corporation. He helped launch the Health Sciences business unit and successfully led two acquisitions for Oracle in Life Sciences. Before joining Oracle, Mr. Joshi served in senior strategy roles with IBM’s Global Sales and Distribution organization, and prior to IBM, Mr. Joshi was at McKinsey and Company, where he worked with Fortune 500 companies on strategy issues.
     
    Mr. Joshi holds a B.S. in mathematics from the California Institute of Technology and a Ph.D. in physics from the Massachusetts Institute of Technology. He currently serves on the boards of the Personalized Medicine Coalition and the eHealth Initiative in Washington, DC.

  • TIM SUTHER

    CNBC Read Bio ⟶

    Kate Rooney

    Tim Suther is senior vice president and general manager, Data Solutions for Change Healthcare. In this leadership role, he focuses on inspiring a better healthcare system through the effective and responsible use of data and analytics.

    Mr. Suther’s career spans more than three decades of maximizing commercial and societal value through data, analytics and technology transformation. Previous roles included founder and entrepreneur (Suther Strategic LLC), managing director, Intelligent Solutions (JPMorgan Chase), chief marketing and strategy officer (Acxiom), senior vice president (Metavante), president (Protagona Worldwide), and a variety of roles at Unisys.

    He is a member of the board of directors at Label Insight and at Commerce Signals, two companies focused on innovative uses of data. He is a member of the Loras College Board of Regents and a member of its Executive Committee. He was named an ExecRank Top CMO in 2012, a Social Media Marketing Top CMO on Twitter, a BlueFocus Marketing Nifty50 Men in Technology. He won the CMO Club Presidents Award in 2015.

    Suther holds a degree in finance and marketing from Loras College.

  • SHIBANI JOSHI

    CNBC Read Bio ⟶

    Kate Rooney

    Shibani Joshi is an experienced journalist who has covered business, technology and general news for global media outlets including ABC News, Fox News Channel, Yahoo! Finance and Huffington Post. She provides commentary on business, technology and lifestyle topics and hosts events for leading corporations.

    Previously, Shibani anchored a daily markets show and had her own dedicated segment on TV called “Joshi on Tech” on the Fox Business Network in New York City. In her almost 6-year tenure, she evolved into the dedicated on-air tech reporter at both Fox News Channel and Fox Business Network.

    Shibani also reported extensively live on the floor of the New York Stock Exchange, Nasdaq and NYMex exchanges, covering the 2008 market crash, historic interest rate cuts, record oil prices and the biggest point drop in Dow history (at the time).

    Throughout her career, Shibani has interviewed large-cap tech CEOs and executives from companies including Apple, Qualcomm, Google, Sony and Ebay. She has also interviewed execs from Uber, Dropbox, Rent the Runway and Angie’s List in their early stages.

    Her unique business perspective stems from real-world corporate experience and a distinguished business education. After double majoring in finance and accounting, she worked as an investment banking analyst at Morgan Stanley in New York City, where she focused on corporate finance and M&A projects.

    Joshi later moved on to Disney/ABC Media Networks, where she was the firm’s Senior Manager of Digital Strategy. In 2014, she created ShibanionTech.com, a blog focused on stories at the intersection of lifestyle and technology.
    Shibani teaches at the University of Oklahoma, sits on the Board of Advisors for the Price College of Business at the University of Oklahoma, and served as a Trustee to The Children’s School in La Jolla, California.

    Shibani is a graduate of the University of Oklahoma and holds an MBA from The Harvard Business School. She currently lives in the Bay Area with her 3 children.

  • MEG TIRRELL

    CNBC Read Bio ⟶

    Kate Rooney

    Meg Tirrell joined CNBC in April 2014 as a general assignment reporter focusing on biotechnology and pharmaceuticals. She appears on CNBC's Business Day programming, contributes to CNBC.com and is based at the network's global headquarters in Englewood Cliffs, N.J.

    Tirrell has covered development of new drugs for Alzheimer's, cancer and rare diseases, and tracked public health emergencies from Ebola to Zika. Her work has explored why fewer drugs are developed for children, chronicled the sequencing of her own genome, and followed the manufacturing of a flu shot from egg to pharmacy. In 2014, she revealed the agonizing decision-making behind Compassionate Use of unapproved drugs, and in 2016, she reported extensively on drug pricing controversies and the impact of politics on development of new medicines.

    Prior to joining CNBC, Tirrell covered the biotechnology industry for Bloomberg News, where she also contributed to Bloomberg Television and Bloomberg Businessweek.

    She holds a master's degree in journalism from Northwestern University and a bachelor's degree in English and music from Wellesley College.

  • BERTHA COOMBS

    CNBC Read Bio ⟶

    Kate Rooney

    Bertha Coombs is a reporter for CNBC, covering financial markets, business news stories and health care throughout the business day. She is based at the Nasdaq Marketsite in Times Square.

    Her health care coverage at CNBC has ranged from covering the implementation of the Affordable Care Act and the failed launch of the Obamacare health insurance exchanges, to how cancer researchers are using IBM's Watson to improve cancer care, and how doctors are using mobile technology to treat patients in their own homes. She also covered the devastation of Hurricane Katrina in New Orleans, the impact of the financial crisis of 2008, and reported on the oil markets from the floor of the New York Mercantile exchange.

    Before joining CNBC, Coombs was a reporter and anchor for the pioneering online business network, Yahoo Finance Vision, and served as a freelance reporter for the former CNNfn financial network. Prior, she served as a reporter for ABC News One, and a substitute anchor for "World News Now" and "World News This Morning."

    She began her career in general news, with previous reporting and anchoring positions at WABC-TV in New York, WPLG-TV in Miami and WFSB-TV in Hartford, Connecticut.

    Coombs is a graduate of Yale University and was awarded the Leo Beranek Reporter Training Fellowship at WCVB-TV in Boston. Born in Havana, Cuba, she speaks fluent Spanish.

  • SHARON EPPERSON

    CNBC Read Bio ⟶

    Kate Rooney

    Sharon Epperson, named one of “12 to Watch in TV News,” can be seen regularly on CNBC television and other media platforms.

    As CNBC’s senior personal finance correspondent, Epperson covers the many facets of how people manage, grow and protect their money. Her expertise includes saving and investing for retirement, paying for college, managing mortgage, student loan, credit card and other debt, and building a financial legacy through estate planning.

    Preparing your finances for the unexpected is another critical (and personal) aspect of her reporting. In September 2016, Epperson sustained a ruptured brain aneurysm and she nearly lost her life. She has become a staunch advocate for health and wellness issues, raising awareness about brain aneurysms and funding for research. In September 2018, she and her family established “The Sharon Epperson Chair of Research” through the Brain Aneurysm Foundation to provide grants for research on early detection and innovative treatments.

    Epperson is a lead contributor to “Invest in You: Ready. Set. Grow.,” a multi-platform financial wellness and education initiative at CNBC in partnership with the micro-investing app Acorns, and developed its companion 8-week learning course and weekly newsletter, “Invest in You: Money 101.” She also contributes to NBC’s TODAY and NBC Nightly News as well as Today.com and NBCNews.com.

    Her book, The Big Payoff: 8 Steps Couples Can Take to Make the Most of Their Money-and Live Richly Ever After, was a finalist for the Books for a Better Life Awards, honoring works that have “changed the lives of millions.” She also was a contributing writer for The Experts’ Guide to Doing Things Faster. Her personal finance expertise has been featured in numerous publications, including The Wall Street Journal, The Washington Post, The Boston Globe, USA Weekend, Self, Essence, Ebony and TIME, where she had covered business, culture, social issues and health as a correspondent prior to joining CNBC.

    Epperson has numerous industry and civic awards, including the Special Achievement Award from the National Association of Personal Financial Advisors (NAPFA) and the Savvy Inspiration Award from the non-profit, financial empowerment group Savvy Ladies. She won an Alliance for Women in Media’s Gracie Award for Outstanding Online Host for her “Financial Advisor Playbook” video series on CNBC.com. She has received the Vanguard Award for her distinguished career in business and personal finance reporting from the National Urban League Guild, and the All-Star Award from the Association of Women in Communications. She also has won awards from the New York Festivals, the New York Association of Black Journalists and the National Association of Black Journalists.

    Epperson is committed to improving financial literacy, particularly in underserved communities. She was invited to the White House during President Obama’s administration to speak about financial literacy and to moderate a public meeting of the President’s Advisory Council on Financial Capability at the U.S. Treasury Department. She also speaks frequently at conferences and events for local and national organizations, colleges and universities about many facets of personal finance.

    An adjunct professor at Columbia University’s School of International and Public Affairs, Epperson has also taught courses at Columbia’s Graduate School of Journalism. She enjoys teaching the importance of budgeting and building long-term savings as part of her professional development courses for graduate students.

    Epperson received her bachelor’s in sociology and government from Harvard University, a master of international affairs degree from Columbia University, and an honorary doctorate from Carlow University in Pittsburgh. A Pittsburgh native, she has also been inducted into the Hall of Fame at Taylor Allderdice High School, her alma mater.

    She currently lives with her husband and two children in Westchester County, N.Y.

  • BERKELEY LOVELACE JR.

    CNBC Read Bio ⟶

    Kate Rooney

    Berkeley Lovelace Jr. is a health-care reporter for CNBC.com, mainly covering pharmaceuticals and the Food and Drug Administration. He’s also the host of “Healthy Returns,” a weekly health-care newsletter. Follow him on Twitter @BerkeleyJr.

    He began working for CNBC in 2016 as a fellow before becoming a news associate and later a staff reporter. He holds a BA in Journalism from the University of Missouri.

  • KATE ROONEY

    CNBC Read Bio ⟶

    Kate Rooney

    Kate Rooney is a technology reporter based out of CNBC’s San Francisco bureau, with a focus on financial technology, payments and venture capital. She also writes and reports for CNBC’s digital platforms.

    Rooney joined CNBC in 2015 as a news associate before working as a producer for CNBC’s “Squawk Box” (M-F, 6AM-9AM ET) and was most recently a markets reporter for CNBC.com.

    She graduated from Boston College with a bachelor’s degree in communication and earned her master’s degree from the Medill School of Journalism at Northwestern University where she received an Eric Lund Global Reporting and Research Grant to film and produce a documentary in the Philippines. She also worked as a multimedia reporter in Buenos Aires, Argentina in 2015 with a focus on housing and politics.

AGENDA

12:30pmEST

Doors Open

12:45pmEST

Join the Live Chat

Share your thoughts, shape the conversation
Healthy Returns Spotlight will kick off with a CNBC moderated attendee-driven chat. Topics include; vaccine distribution, how the new administration should handle this phase of the pandemic, what’s ahead for the health care industry, and more. We invite you to share your thoughts with peers in your industry and weigh in on critical issues facing health care now and in the future.  
Moderator: Berkeley Lovelace, Health Care Reporter, CNBC

1:00pmEST

Operation Inoculate

Retail pharmacies will play a vital role inoculating Americans from every corner of the country, amidst massive logistical and staffing challenges. We’ll get a behind-the-scenes look at the obstacles they face, and their role to help end the pandemic. 
Rick GatesSVP, Pharmacy & Healthcare, Walgreens 
Interviewer: Meg Tirrell, Senior Health & Science Reporter, CNBC
Watch the full interview

1:15pmEST

Hospital CEO: Pandemic Playbook

When Covid hit, hospitals were without a playbook on how to navigate the sudden onslaught of sick patients, shutdown of outpatient services, operational challenges, lost revenue, and more. One CEO will join us to talk about lessons learned, and strategies for the future.
Anita Jenkins, CEO, Howard University Hospital
Interviewer: Bertha Coombs, Reporter, CNBC
Watch the full interview

1:25pmEST

New Covid Threat: Cybercriminals

As the Covid-19 vaccine rollout continues, cybersecurity experts are sounding the alarm over growing threats of tampering and theft by cybercriminals targeting the supply chain. We’ll discuss who’s most at risk, and what can be done to stop potential hacks before they happen.
Marc Rogers, former hacker/Executive Director of Cybersecurity, Okta
Interviewer: Kate Rooney, Technology Reporter, CNBC
Watch the full interview

1:40pmEST

Breakout Sessions

Data Analytics, Vaccine Passports & the Path to a New Normal
Sponsored and programmed by Change Healthcare
In this session, we will explore how securely leveraging key social determinants of health (SDoH) data can better inform provider approaches for individual patients, and accelerate a consumer-friendly approach to normalcy during and after the Covid pandemic through the implementation of vaccine passports.
Tim Suther, SVP and General Manager, Data Solutions, Change Healthcare
Kris Joshi, EVP, Network Solutions, Change Healthcare
Moderator: Shibani Joshi, Technology Journalist
Watch the full interview

 

Mental HealthAn Out-of-the-Box Approach
With the US in the midst of what’s being called the worst mental health crisis in decades, one expert is taking an unconventional approach to reaching individuals who need help, using the unlikeliest of tech platforms.
Alok Kanojia, MD, Psychiatrist; President, Healthy Gamer
Interviewer: Sharon Epperson, Senior Personal Finance Correspondent, CNBC
Watch the full interview

2:00pmEST

High Hopes: Vaccine Update

Johnson & Johnson’s Covid-19 vaccine is being hailed as a potential “game changer,” because of its single dose. We’ll receive an update from the company’s CEO on the status of FDA approval, along with an exclusive look into the process of developing a life-saving vaccine. 
Alex Gorsky, CEO, Johnson & Johnson
Interviewer: Meg Tirrell, Senior Health & Science Reporter, CNBC
Watch the full interview

2:30pmEST

Program Concludes

LEARN MORE & SUBSCRIBE

REGISTER FOR OUR ANNUAL SUMMIT – May 11, 2021.

Subscribe to our Healthy Returns newsletter for exclusive insights on the biggest health care news from our reporters, delivered straight to your inbox every Friday.

You can also visit cnbc.com/healthy-returns for relevant content from the event and all-things health care investing and innovation.

SPONSORED BY

SPONSORED BY

PAST SPEAKERS

Giovanni
Caforio

Bristol Myers Squibb

Giovanni Caforio, M.D. is Chairman of the Board and CEO of Bristol Myers Squibb.

Giovanni Caforio

Giovanni Caforio, M.D., is Chairman of the Board and chief executive officer of Bristol Myers Squibb. Under Giovanni’s leadership, BMS is delivering innovative medicines to treat patients with cancer, auto-immune diseases and cardiovascular disease, and is advancing one of the most diverse and promising pipelines in the industry. Giovanni leads a diverse global workforce dedicated to the company’s mission of discovering, developing and delivering innovative medicines that help patients prevail over serious diseases.

Giovanni was appointed CEO in 2015 and elected as Chairman of the Board of Directors in 2017. As part of Bristol Myers Squibb’s strategy to combine the agility of a biotech with the reach and scale of an established pharma company, Giovanni led the company’s acquisition of Celgene in 2019. Today the company is a leading biopharma company focused on transforming patients’ lives through science. He has developed a strong patient-focused culture, with teams who are passionate about the work they do to help address some of the most challenging diseases of our time. He has led BMS’ drive to promote an inclusive culture where employees are encouraged to challenge the status quo and bring forward solutions.

Giovanni is an active champion for a policy environment that values healthcare innovation and supports patient access to medicines. Reflecting his advocacy, in 2015 he joined the Board of Directors for the Pharmaceutical Research and Manufacturers of America, known as PhRMA, and in 2019 was named Chairman.
Prior to becoming CEO, Giovanni served as chief operating officer with responsibility for leading a fully integrated worldwide commercial organization and the companywide functions of Enterprise Services and Global Manufacturing & Supply. This was preceded by appointment as the company’s chief commercial officer.

Born and educated in Italy, Giovanni received his medical doctorate from the University of Rome. He started his career with Abbott Laboratories before joining Bristol-Myers Squibb in 2000 as vice president and general manager, Italy, in the Worldwide Medicines Group. Giovanni advanced through a series of regional European management positions and, in 2004, became senior vice president, European Marketing and Brand Commercialization. In 2007, he relocated to the U.S. as senior vice president, U.S. Oncology. He was named senior vice president, Global Commercialization, Oncology and Immunology in 2010, then became president of the company’s U.S. organization in 2011.

Stéphane
Bancel

Moderna

Stéphane Bancel is Chief Executive Officer of Moderna.

Stéphane Bancel

Stéphane Bancel has served as Moderna's Chief Executive Officer since October 2011 and as a member of Moderna’s board of directors since March 2011. Before joining the Company, Mr. Bancel served for five years as Chief Executive Officer of the French diagnostics company bioMérieux SA. From July 2000 to March 2006, he served in various roles at Eli Lilly and Company, including as Managing Director, Belgium and as Executive Director, Global Manufacturing Strategy and Supply Chain. Prior to Lilly, Mr. Bancel served as Asia-Pacific Sales and Marketing Director for bioMérieux.

Mr. Bancel currently serves on the board of directors of Qiagen N.V. and previously served on the board of directors of BG Medicine, Inc. and Syros Pharmaceuticals, Inc. (Nasdaq: SYRS). He is currently a Venture Partner at Flagship Pioneering and a trustee of the Museum of Science in Boston. Mr. Bancel holds a Master of Engineering degree from École Centrale Paris (ECP), a Master of Science in chemical engineering from the University of Minnesota, and an M.B.A. from Harvard Business School.

Martine
Rothblatt

United Therapeutics

Martine Rothblatt is Chairman & CEO of United Therapeutics.

Martine Rothblatt

Martine Rothblatt is Chairman & CEO of United Therapeutics, a biotechnology company she started to save the life of one of her daughters. The company offers FDA approved medicines for pulmonary hypertension and neuroblastoma and is working on manufacturing an unlimited supply of transplantable organs.

Dr. Rothblatt previously created and led Sirius XM as its Chairman & CEO, and launched other satellite systems for navigation and international television broadcasting. In the field of aviation her Sirius XM satellite system enhances safety with real-time digital weather information to pilots in flight nationwide. She also designed the world’s first electric helicopter, which in 2018 set Guinness world records for distance and flight duration.

In the legal arena, Dr. Rothblatt led efforts to create transgender health law standards, and to protect privacy and autonomy rights in genetic information via an international treaty. She has Bachelor’s (Communications Studies, Summa Cum Laude), JD and MBA degrees from UCLA, and a Ph.D. in Medical Ethics from the Royal London School of Medicine & Dentistry. Her patented inventions cover aspects of satellite radio, prostacyclin biochemistry and cognitive software. Dr. Rothblatt’s recent books are on xenotransplantation (Your Life or Mine), non-binary gender identity (Transgender to Transhuman) and cyberethics (Virtually Human).

Alex
Gorsky

Johnson & Johnson

Alex Gorsky is Chairman of the Board and Chief Executive Officer of Johnson & Johnson and Chairman of the Executive Committee.

Alex Gorsky

Alex Gorsky is Chairman of the Board and Chief Executive Officer of Johnson & Johnson and Chairman of the Executive Committee, the Company’s senior leadership team. Alex is the seventh person to serve as Chairman and CEO of Johnson & Johnson since it became a publicly traded company in 1944.

Alex began his Johnson & Johnson career as a sales representative with Janssen Pharmaceutica in 1988. Over the next 15 years, he advanced through positions of increasing responsibility in sales, marketing and management including assignments in the U.S., Europe, Africa and the Middle East. He progressed through many management posts at J&J, culminating in being named Chief Executive Officer on April 26, 2012 and Chairman of the Board on December 28, 2012.

Under Alex Gorsky’s leadership, Johnson & Johnson continues in its 132nd year to be one of the world’s exceptional corporations. The company was given the #1 ranking on Barron’s Magazine’s 2016 list of the “World’s Most Admired Companies,” and is currently the number one Pharmaceutical company on Fortune Magazine’s list of the “World’s Most Respected Companies.

A longtime advocate of Diversity Inclusion and Veteran’s issues, Alex has been named one of the “100 Most Inspiring Leaders” by Pharma Voice. Most recently, in December of 2017, Alex received the Ripple of Hope Award from the Robert F. Kennedy Human Rights Foundation. And for the past three years, Alex has been on the list of the Highest Rated CEOs on The Glassdoor Employees’ Choice Awards. He has also received the Jackie Robinson Award, Appeal of Conscience Award, the Joseph Wharton Leadership Award and the CADCA Humanitarian of the Year Award.

Alex is a member of the Board of Directors of IBM, the Wharton School of Business Board of Overseers and the Board of Directors of the Business Roundtable.

Alex holds a Bachelor of Science degree from the U.S. Military Academy at West Point, N.Y., and spent six years in the U.S. Army, finishing his military career with the rank of Captain. Alex earned a Master of Business Administration degree from The Wharton School of the University of Pennsylvania in 1996.

Vasant
Narasimhan

Novartis

Vasant Narasimhan, M.D., is Chief Executive Officer of Novartis.

Vasant Narasimhan

Vasant (Vas) Narasimhan, M.D., has been Chief Executive Officer (CEO) of Novartis since February 1, 2018.

Dr. Narasimhan previously was Global Head of Drug Development and Chief Medical Officer for Novartis. He has also served as Global Head of Development for Novartis Pharmaceuticals, Global Head of the Sandoz Biopharmaceuticals and Oncology Injectables business unit, Global Head of Development for Novartis Vaccines, North America Region Head for Novartis Vaccines, and United States Country President for Novartis Vaccines and Diagnostics. Before joining Novartis in 2005, he worked at McKinsey & Company.

Dr. Narasimhan received his medical degree from Harvard Medical School in the US, a master’s degree in public policy from Harvard’s John F. Kennedy School of Government, and a bachelor’s degree in biological sciences from the University of Chicago in the US. During and after his medical studies, he worked extensively on a range of public health issues in developing countries. He is an elected member of the US National Academy of Medicine and serves on the board of fellows of Harvard Medical School.

Leonard
Schleifer

Regeneron Pharmaceuticals

Leonard Schleifer is Founder, President and CEO of Regeneron Pharmaceuticals.

Leonard Schleifer

Leonard S. Schleifer, MD, PhD, founded Regeneron Pharmaceuticals in 1988 while serving as an Assistant Professor of Neurology at Weill Cornell Medical College. Leveraging a lifelong passion for science and an entrepreneurial spirit, he has served as a director, its president and chief executive officer since its inception and acted as chairman of the board from 1990 through 1994. Schleifer received his MD and PhD in Pharmacology from the University of Virginia, and he is a licensed physician certified in neurology by the American Board of Psychiatry and Neurology.

Daphne
Koller

insitro

Daphne Koller is Founder and CEO of insitro.

Daphne Koller

Daphne Koller brings to insitro her many years of experience in the areas of machine learning, statistical modeling, computational biology, and computational medicine. She was the Rajeev Motwani Professor of Computer Science at Stanford University, where she was hired as the first machine learning professor in 1995 and served on the faculty for 18 years. Her work in machine learning spans a broad range of topics, including probabilistic graphical models, structured prediction, active learning, time series modeling, reinforcement learning, and many more. She was also one of the pioneers in applying machine learning to biomedical data sets, and has worked on topics such as reconstruction of regulatory networks, phenotypic effects of genetic variation, and interpretation of microscopy images in cancer. She is the author of over 200 refereed publications appearing in diverse venues such as NIPS, ICML, Science, Cell, and Nature Genetics, and has an h-index of over 120. She is also the author of the leading textbook on Probabilistic Graphical Models.

Daphne co-founded Coursera in 2012, where she served as the company’s Co-CEO until 2014, and then as President until 2016. Coursera is the world’s largest online education platform with over 30 million learners worldwide, and over 150 university partners in six continents. She is currently the Co-Chair of the Coursera Board. Most recently, Daphne served as the Chief Computing Officer at Calico Labs, an Alphabet (Google) company that is using advanced technology to understand aging and design interventions that help people lead longer, healthier lives.

Daphne was recognized as one of TIME Magazine’s 100 most influential people in 2012 and Newsweek’s 10 most important people in 2010. She has been honored with multiple awards and fellowships during her career including the Sloan Foundation Faculty Fellowship in 1996, the ONR Young Investigator Award in 1998, the Presidential Early Career Award for Scientists and Engineers (PECASE) in 1999, the IJCAI Computers and Thought Award in 2001, the MacArthur Foundation Fellowship in 2004, and the ACM Prize in Computing in 2008. Daphne was inducted into the National Academy of Engineering in 2011 and elected a fellow of the American Academy of Arts and Sciences in 2014 and of the International Society of Computational Biology in 2017.

Scarlet
Shore

Verily

Scarlet is head of product and platform lead for Project Baseline at Verily.

Scarlet Shore

Scarlet is the head of product and platform lead for Project Baseline, Verily's bold initiative to map human health and democratize research. Prior to joining Verily, Scarlet held roles in product, strategy, and business development at a variety of life science and technology companies. Scarlet received her B.A. from the University of Pennsylvania and was a faculty scholar at the NYU Stern School of Business.

PAST SPEAKERS

  • GIOVANNI CAFORIO

    Bristol Myers Squibb

    Read Bio ⟶

    GIOVANNI CAFORIO

    Giovanni Caforio, M.D., is Chairman of the Board and chief executive officer of Bristol Myers Squibb. Under Giovanni’s leadership, BMS is delivering innovative medicines to treat patients with cancer, auto-immune diseases and cardiovascular disease, and is advancing one of the most diverse and promising pipelines in the industry. Giovanni leads a diverse global workforce dedicated to the company’s mission of discovering, developing and delivering innovative medicines that help patients prevail over serious diseases.

    Giovanni was appointed CEO in 2015 and elected as Chairman of the Board of Directors in 2017. As part of Bristol Myers Squibb’s strategy to combine the agility of a biotech with the reach and scale of an established pharma company, Giovanni led the company’s acquisition of Celgene in 2019. Today the company is a leading biopharma company focused on transforming patients’ lives through science. He has developed a strong patient-focused culture, with teams who are passionate about the work they do to help address some of the most challenging diseases of our time. He has led BMS’ drive to promote an inclusive culture where employees are encouraged to challenge the status quo and bring forward solutions.

    Giovanni is an active champion for a policy environment that values healthcare innovation and supports patient access to medicines. Reflecting his advocacy, in 2015 he joined the Board of Directors for the Pharmaceutical Research and Manufacturers of America, known as PhRMA, and in 2019 was named Chairman.
    Prior to becoming CEO, Giovanni served as chief operating officer with responsibility for leading a fully integrated worldwide commercial organization and the companywide functions of Enterprise Services and Global Manufacturing & Supply. This was preceded by appointment as the company’s chief commercial officer.

    Born and educated in Italy, Giovanni received his medical doctorate from the University of Rome. He started his career with Abbott Laboratories before joining Bristol-Myers Squibb in 2000 as vice president and general manager, Italy, in the Worldwide Medicines Group. Giovanni advanced through a series of regional European management positions and, in 2004, became senior vice president, European Marketing and Brand Commercialization. In 2007, he relocated to the U.S. as senior vice president, U.S. Oncology. He was named senior vice president, Global Commercialization, Oncology and Immunology in 2010, then became president of the company’s U.S. organization in 2011.

  • STéPHANE BANCEL

    Moderna

    Read Bio ⟶

    STéPHANE BANCEL

    Stéphane Bancel has served as Moderna's Chief Executive Officer since October 2011 and as a member of Moderna’s board of directors since March 2011. Before joining the Company, Mr. Bancel served for five years as Chief Executive Officer of the French diagnostics company bioMérieux SA. From July 2000 to March 2006, he served in various roles at Eli Lilly and Company, including as Managing Director, Belgium and as Executive Director, Global Manufacturing Strategy and Supply Chain. Prior to Lilly, Mr. Bancel served as Asia-Pacific Sales and Marketing Director for bioMérieux.

    Mr. Bancel currently serves on the board of directors of Qiagen N.V. and previously served on the board of directors of BG Medicine, Inc. and Syros Pharmaceuticals, Inc. (Nasdaq: SYRS). He is currently a Venture Partner at Flagship Pioneering and a trustee of the Museum of Science in Boston. Mr. Bancel holds a Master of Engineering degree from École Centrale Paris (ECP), a Master of Science in chemical engineering from the University of Minnesota, and an M.B.A. from Harvard Business School.

  • MARTINE ROTHBLATT

    United Therapeutics

    Read Bio ⟶

    MARTINE ROTHBLATT

    Martine Rothblatt is Chairman & CEO of United Therapeutics, a biotechnology company she started to save the life of one of her daughters. The company offers FDA approved medicines for pulmonary hypertension and neuroblastoma and is working on manufacturing an unlimited supply of transplantable organs.

    Dr. Rothblatt previously created and led Sirius XM as its Chairman & CEO, and launched other satellite systems for navigation and international television broadcasting. In the field of aviation her Sirius XM satellite system enhances safety with real-time digital weather information to pilots in flight nationwide. She also designed the world’s first electric helicopter, which in 2018 set Guinness world records for distance and flight duration.

    In the legal arena, Dr. Rothblatt led efforts to create transgender health law standards, and to protect privacy and autonomy rights in genetic information via an international treaty. She has Bachelor’s (Communications Studies, Summa Cum Laude), JD and MBA degrees from UCLA, and a Ph.D. in Medical Ethics from the Royal London School of Medicine & Dentistry. Her patented inventions cover aspects of satellite radio, prostacyclin biochemistry and cognitive software. Dr. Rothblatt’s recent books are on xenotransplantation (Your Life or Mine), non-binary gender identity (Transgender to Transhuman) and cyberethics (Virtually Human).

  • ALEX GORSKY

    Johnson & Johnson

    Read Bio ⟶

    ALEX GORSKY

    Alex Gorsky is Chairman of the Board and Chief Executive Officer of Johnson & Johnson and Chairman of the Executive Committee, the Company’s senior leadership team. Alex is the seventh person to serve as Chairman and CEO of Johnson & Johnson since it became a publicly traded company in 1944.

    Alex began his Johnson & Johnson career as a sales representative with Janssen Pharmaceutica in 1988. Over the next 15 years, he advanced through positions of increasing responsibility in sales, marketing and management including assignments in the U.S., Europe, Africa and the Middle East. He progressed through many management posts at J&J, culminating in being named Chief Executive Officer on April 26, 2012 and Chairman of the Board on December 28, 2012.

    Under Alex Gorsky’s leadership, Johnson & Johnson continues in its 132nd year to be one of the world’s exceptional corporations. The company was given the #1 ranking on Barron’s Magazine’s 2016 list of the “World’s Most Admired Companies,” and is currently the number one Pharmaceutical company on Fortune Magazine’s list of the “World’s Most Respected Companies.

    A longtime advocate of Diversity Inclusion and Veteran’s issues, Alex has been named one of the “100 Most Inspiring Leaders” by Pharma Voice. Most recently, in December of 2017, Alex received the Ripple of Hope Award from the Robert F. Kennedy Human Rights Foundation. And for the past three years, Alex has been on the list of the Highest Rated CEOs on The Glassdoor Employees’ Choice Awards. He has also received the Jackie Robinson Award, Appeal of Conscience Award, the Joseph Wharton Leadership Award and the CADCA Humanitarian of the Year Award.

    Alex is a member of the Board of Directors of IBM, the Wharton School of Business Board of Overseers and the Board of Directors of the Business Roundtable.

    Alex holds a Bachelor of Science degree from the U.S. Military Academy at West Point, N.Y., and spent six years in the U.S. Army, finishing his military career with the rank of Captain. Alex earned a Master of Business Administration degree from The Wharton School of the University of Pennsylvania in 1996.

  • VASANT “VAS” NARASIMHAN

    Novartis

    Read Bio ⟶

    VASANT “VAS” NARASIMHAN

    Vasant (Vas) Narasimhan, M.D., has been Chief Executive Officer (CEO) of Novartis since February 1, 2018.

    Dr. Narasimhan previously was Global Head of Drug Development and Chief Medical Officer for Novartis. He has also served as Global Head of Development for Novartis Pharmaceuticals, Global Head of the Sandoz Biopharmaceuticals and Oncology Injectables business unit, Global Head of Development for Novartis Vaccines, North America Region Head for Novartis Vaccines, and United States Country President for Novartis Vaccines and Diagnostics. Before joining Novartis in 2005, he worked at McKinsey & Company.

    Dr. Narasimhan received his medical degree from Harvard Medical School in the US, a master’s degree in public policy from Harvard’s John F. Kennedy School of Government, and a bachelor’s degree in biological sciences from the University of Chicago in the US. During and after his medical studies, he worked extensively on a range of public health issues in developing countries. He is an elected member of the US National Academy of Medicine and serves on the board of fellows of Harvard Medical School.

  • LEONARD S. SCHLEIFER

    Regeneron Pharmaceuticals

    Read Bio ⟶

    LEONARD S. SCHLEIFER

    Leonard S. Schleifer, MD, PhD, founded Regeneron Pharmaceuticals in 1988 while serving as an Assistant Professor of Neurology at Weill Cornell Medical College. Leveraging a lifelong passion for science and an entrepreneurial spirit, he has served as a director, its president and chief executive officer since its inception and acted as chairman of the board from 1990 through 1994. Schleifer received his MD and PhD in Pharmacology from the University of Virginia, and he is a licensed physician certified in neurology by the American Board of Psychiatry and Neurology.

  • DAPHNE KOLLER

    insitro

    Read Bio ⟶

    DAPHNE KOLLER

    Daphne Koller brings to insitro her many years of experience in the areas of machine learning, statistical modeling, computational biology, and computational medicine. She was the Rajeev Motwani Professor of Computer Science at Stanford University, where she was hired as the first machine learning professor in 1995 and served on the faculty for 18 years. Her work in machine learning spans a broad range of topics, including probabilistic graphical models, structured prediction, active learning, time series modeling, reinforcement learning, and many more. She was also one of the pioneers in applying machine learning to biomedical data sets, and has worked on topics such as reconstruction of regulatory networks, phenotypic effects of genetic variation, and interpretation of microscopy images in cancer. She is the author of over 200 refereed publications appearing in diverse venues such as NIPS, ICML, Science, Cell, and Nature Genetics, and has an h-index of over 120. She is also the author of the leading textbook on Probabilistic Graphical Models.

    Daphne co-founded Coursera in 2012, where she served as the company’s Co-CEO until 2014, and then as President until 2016. Coursera is the world’s largest online education platform with over 30 million learners worldwide, and over 150 university partners in six continents. She is currently the Co-Chair of the Coursera Board. Most recently, Daphne served as the Chief Computing Officer at Calico Labs, an Alphabet (Google) company that is using advanced technology to understand aging and design interventions that help people lead longer, healthier lives.

    Daphne was recognized as one of TIME Magazine’s 100 most influential people in 2012 and Newsweek’s 10 most important people in 2010. She has been honored with multiple awards and fellowships during her career including the Sloan Foundation Faculty Fellowship in 1996, the ONR Young Investigator Award in 1998, the Presidential Early Career Award for Scientists and Engineers (PECASE) in 1999, the IJCAI Computers and Thought Award in 2001, the MacArthur Foundation Fellowship in 2004, and the ACM Prize in Computing in 2008. Daphne was inducted into the National Academy of Engineering in 2011 and elected a fellow of the American Academy of Arts and Sciences in 2014 and of the International Society of Computational Biology in 2017.

  • SCARLET SHORE

    Verily

    Read Bio ⟶

    SCARLET SHORE

    Scarlet is the head of product and platform lead for Project Baseline, Verily's bold initiative to map human health and democratize research. Prior to joining Verily, Scarlet held roles in product, strategy, and business development at a variety of life science and technology companies. Scarlet received her B.A. from the University of Pennsylvania and was a faculty scholar at the NYU Stern School of Business.

  • SAMARTH KULKARNI

    CRISPR Therapeutics

    Read Bio ⟶

    SAMARTH KULKARNI

    Dr. Samarth Kulkarni has served as Chief Executive Officer of CRISPR Therapeutics since December 2017.

    He has significant expertise in strategy and operations in biotech and a wide range of related cutting-edge therapeutic technologies. He joined CRISPR in August 2015 in the early stages of the company as Chief Business Officer, and then served as President and Chief Business Officer starting May 2017. Prior to joining CRISPR, Sam was a Partner at McKinsey & Company, where he had a leading role in the Pharmaceutical and Medical products practice. While at McKinsey, he co-led the biotech practice, served a number of biotechnology companies on topics ranging from strategy to operations and led initiatives in areas such as personalized medicine and immunotherapy. Sam also serves as a member of the Casebia Board of Directors.

    He received a Ph.D. in Bioengineering and Nanotechnology from the University of Washington and a B. Tech. from the Indian Institute of Technology. While at the University of Washington, he conducted research in the delivery of biological drugs and in the field of molecular diagnostics. He has authored several publications in leading scientific and business journals.

  • JENNIFER SCHNEIDER

    Livongo

    Read Bio ⟶

    JENNIFER SCHNEIDER

    Dr. Jennifer Schneider is the President of Livongo. In this role, she is responsible for product, data science, engineering, marketing, and clinical operations. Dr. Schneider previously served as the company’s Chief Medical Officer where she led the company’s strategic clinical product vision, data science, clinical trials, and the organization’s certified diabetes educators and coaches.

    Prior to Livongo, Dr. Schneider held several key leadership roles at Castlight Health, most recently as Chief Medical Officer. She also has held leadership roles in the provider setting as a health outcomes researcher and Chief Resident at Stanford University, and has practiced medicine as an attending physician at Stanford University, the VA Palo Alto Health Care System, and Kaiser Permanente. Dr. Schneider has an undergraduate degree from the College of the Holy Cross, a Doctor of Medicine degree from Johns Hopkins School of Medicine, and a Master of Science degree in Health Services Research from Stanford University. She completed her internal medicine residency at Stanford University Hospital.

    Dr. Schneider is a frequent speaker about innovation in healthcare, where she shares her unique perspective as a practicing physician, health services researcher, senior executive and individual who has lived with Type 1 diabetes for more than 30 years. She has three children and is an avid runner and athlete, having completed her first IronMan in 2016.

  • DAVID CORDANI

    Cigna

    Read Bio ⟶

    DAVID CORDANI

    David Cordani became president and CEO of Cigna in 2009 and has spearheaded its transformation into a leading global health service company, doubling the size of the company in six years. He is a prominent voice addressing key health challenges, such as the empowering of individuals to manage their own health, innovating new health delivery models focused on patients’ health improvements and partnering with physicians to focus on wellness, and improving clinical quality. With operations and capabilities in more than thirty countries, Cordani leads Cigna’s approximately 43,000 employees in improving the health, well-being and sense of security of more than 95 million customer relationships.

    Cordani joined Cigna in 1991; his leadership experiences cross critical disciplines of health care services including distribution, marketing, clinical management, underwriting, finance and operations.

    Prior to joining Cigna, Cordani was with Coopers & Lybrand. He actively works with the Achilles International Freedom Team of Wounded Veterans and ChildObesity180, where he is a charter board member. He also supports organizations including March of Dimes and The Juvenile Diabetes Research Foundation. In addition, he is founder of The David and Sherry Cordani Family Foundation, reflecting the Cordani family’s deep commitment to supporting community health and well-being. Cordani was named to the General Mills Board of Directors in 2014 and to the U.S.-India Business Council Board of Directors in 2015.

    David Cordani is an accomplished triathlete, having competed in more than 125 triathlons. He earned a bachelor’s degree from Texas A&M, and an MBA from the University of Hartford.

  • JORGE CONDE

    Andreessen Horowitz

    Read Bio ⟶

    JORGE CONDE

    Jorge Conde is a General Partner at Andreessen Horowitz where he leads investments at the cross section of biology, computer science and health.
    Prior to joining a16z, Jorge served as Chief Strategy Officer for Syros (NASDAQ: SYRS), which is advancing a new wave of medicines that control expression of disease-driving genes to treat cancer and other diseases. He previously served as the company's Chief Financial Officer and Chief Product Officer, leading the platform strategy for Syros' novel gene regulation technology. Jorge also cofounded Knome, a human genome interpretation company acquired by Tute Genomics in 2015. Earlier in his career, Jorge worked in marketing and operations at MedImmune and as a biotechnology investment banker at Morgan Stanley.

    Jorge holds an MBA from Harvard Business School, an MS from the Harvard-MIT Division of Health Sciences and Technology, and a BA in Biology from Johns Hopkins University.
    Jorge was named one of the top 35 young innovators in the world by the MIT Technology Review and is a 2015 Henry Crown Fellow of the Aspen Institute and a member of the Aspen Global Leadership Network. He serves on the board of the Museum of Science, Boston.

  • ALETHIA YOUNG

    Cantor Fitzgerald

    Read Bio ⟶

    ALETHIA YOUNG

    Alethia Young is the Large Cap Biotech Analyst and Head of Healthcare Research at Cantor Fitzgerald.

  • PETER LEE

    Microsoft Healthcare

    Read Bio ⟶

    PETER LEE

    Dr. Peter Lee is Corporate Vice President, Microsoft Healthcare. He leads an organization that works on technologies for better and more efficient healthcare, with a special focus on artificial intelligence and cloud computing. Dr. Lee has extensive experience in managing the process of going from basic research to commercial impact. Past illustrative examples include the deep neural networks for simultaneous language translation in Skype, next-generation IoT technologies, and innovative silicon and post-silicon computer architectures for Microsoft’s cloud. He also has a history of advancing more “out of the box” technical efforts, such as experimental under-sea datacenters, augmented-reality experiences for HoloLens and VR devices, digital storage in DNA, and social chatbots such as XiaoIce and Tay. Previously, as an Office Director at DARPA, he led efforts that created operational capabilities in advanced machine learning, crowdsourcing, and big-data analytics, such as the DARPA Network Challenge and Nexus 7. He was formerly the Head of Carnegie Mellon University’s computer science department. As a thought leader, he has spoken and written widely on technology trends and policies, spanning the fields of computing technology, healthcare, and innovation ecosystem. He is a member of the Boards of Directors of the Allen Institute for Artificial Intelligence and the Kaiser Permanente School of Medicine. He served on President’s Commission on Enhancing National Cybersecurity. He has led studies for the National Academies on the impact of federal research investments on economic growth and testified before the US House Science and Technology Committee and the US Senate Commerce Committee.

  • MARC HARRISON

    Intermountain Healthcare

    Read Bio ⟶

    MARC HARRISON

    Dr. Harrison is a pediatric critical care physician with a proven track record as a top operations executive on a global scale. He is leading Intermountain to embrace bold new approaches focused on improving health while continuing to make healthcare more effective, accessible, and affordable. As a result, Intermountain’s 37,000 employees—who are all called caregivers—continue to re-define value-based care and serve people in new ways.

    Dr. Harrison is a national and international thought leader on healthcare transformation and innovation. In 2018, he ranked second among Modern Healthcare’s Most Influential Physician Executives and Leaders. He also tied for second on Modern Healthcare’s list of the 100 Most Influential People in Healthcare.

    Two examples of innovations Intermountain is leading:
    • Intermountain launched Civica Rx, a not-for-profit generic drug manufacturer and distributor, to make generic medications more available and affordable in hospitals across the nation.
    • Intermountain is a founding member of the Utah Alliance for the Determinants of Health, which is a collaboration between numerous community partners designed to proactively address forces that affect people’s health well before they come to a clinic or a hospital, such as chronic hunger, affordable housing, joblessness, personal safety, etc.

    Dr. Harrison’s previous healthcare leadership experience has included service as CEO of Cleveland Clinic Abu Dhabi, chief of international business development at Cleveland Clinic, and chief medical operations officer at Cleveland Clinic.

    He received his undergraduate degree from Haverford College, his medical degree from Dartmouth Medical School, completed a residency at Intermountain’s Primary Children’s Hospital, and a Master of Medical Management at Carnegie Mellon University.

    Dr. Harrison is an all-American triathlete and represented the U.S. at the 2014 World Championships.

  • SUSAN DEVORE

    Premier, Inc.

    Read Bio ⟶

    SUSAN DEVORE

    Susan DeVore is CEO of Premier with approximately 30 years of experience. DeVore’s tenure with Premier has centered on driving innovation in healthcare and leading the industry through profound change by engaging stakeholders to co-develop solutions that support high-quality, efficient and sustainable care delivery models.

    DeVore is an industry-leading thinker who has consistently been named multiple times to Modern Healthcare's 100 Most Influential People and Top 25 Women in Healthcare lists. She recently received the Charlotte Business Journal’s 2018 Women in Business Lifetime Achievement Award, was named to Becker’s Hospital Review’s 2017 100 Great Healthcare Leaders to Know and was recognized as a 2016 UNC Charlotte Distinguished Alumnus.

    DeVore currently serves on the Board of Trustees for the Healthcare Leadership Council; is Board Member of the Coalition to Protect America’s Healthcare; is a Board Member, Finance Committee Member and Audit Committee Chair of the Medicare Rights Center; is a Member of the Charlotte Chamber Executive Committee; is a Member of the Charlotte Executive Leadership Council; and a Member of the UNC Charlotte Board of Trustees. She also serves as a Member of the National Academy of Medicine and the Aspen Health Strategy Group, and most recently joined the Board of Unum Group, a NYSE-listed company, as a Director and Audit Committee Member.

    Under DeVore's leadership, Premier has been named as one of the World's Most Ethical Companies for past 11 years, received the Malcolm Baldrige National Quality Award and earned the Best in KLAS title for Overall Healthcare Management Consulting.

    DeVore obtained a bachelor’s degree from the University of North Carolina at Charlotte and a Master of Management degree from McGill University.

  • BOB SHEEHY

    Fmr. Unitedhealthcare CEO

    Read Bio ⟶

    BOB SHEEHY

    Bob Sheehy is co-founder and CEO of Bright Health, and former CEO of UnitedHealthcare. He was also Executive Partner at Flare Capital.

  • TIM WENTWORTH

    Express Scripts

    Read Bio ⟶

    TIM WENTWORTH

    Tim Wentworth leads Express Scripts and Cigna Services. In this role, Wentworth oversees the Express Scripts business as well as independent services, including eviCore.

    Wentworth formerly served as President and Chief Executive Officer of Express Scripts, where he was responsible for all aspects of the company’s strategic direction and core business. He joined Express Scripts when the company merged with Medco in April 2012. At Medco, he led the employer and key accounts organizations for nearly 14 years. He also served as President and CEO of Accredo, the company's specialty pharmacy.

    Wentworth earned a bachelor's degree in industrial and labor relations from Cornell University and an associate's degree in business from Monroe Community College.

  • RAJAIE BATNIJI

    Collective Health

    Read Bio ⟶

    RAJAIE BATNIJI

    As Collective Health’s Co-Founder and Chief Health Officer, Dr. Rajaie Batniji oversees partnerships with healthcare networks and providers, analytics and research, and Collective Health’s employee health management programs. Collective Health brings together Dr. Batniji’s academic and professional careers as both a physician and as a political economist, and his aspiration to create a better and more efficient health insurance experience.

    Dr. Batniji is also a Clinical Assistant Professor of Medicine at the Stanford University School of Medicine, where he previously trained in Internal Medicine. He received a DPhil in International Relations (Political Economy) from Oxford University, where he was a Marshall Scholar, an MD from UCSF, and BA and MA degrees from Stanford University.

  • PAUL DABROWSKI

    Synthego

    Read Bio ⟶

    PAUL DABROWSKI

    Paul Dabrowski is CEO of Synthego. He founded the company with his brother, Michael Dabrowski, and together they developed the company’s world-class commercial offering for genome engineering. Before Synthego, Paul was the lead digital designer for the Falcon 9 rocket and Dragon spacecraft at SpaceX. He also founded a mobile software company and designed a portable electron microscope for DNA sequencing. Paul was born in Illinois to Polish immigrants and earned his MS/BS in Computer Engineering from the University of Illinois at Urbana-Champaign.

  • EDWARD ELLISON

    The Permanente Federation

    Read Bio ⟶

    EDWARD ELLISON

    Ed Ellison, MD, serves as Executive Medical Director/Chairman of the Board, Southern California Permanente Medical Group (SCPMG); Chairman of the Board and CEO, The Southeast Permanente Medical Group. He also is Co-CEO of The Permanente Federation, LLC, a consortium of all the Permanente Medical Groups in the nation, supporting the work of more than 22,000 Kaiser Permanente physicians in the eight Kaiser Permanente regions across the country.Dr. Ellison joined SCPMG in 1984 as a family medicine physician and has served in multiple roles with the organization. In 2002, Dr. Ellison was appointed area medical director for Orange County and joined SCPMG’s Board of Directors. He is a past recipient of Orange County’s Family Medicine Physician of the Year. After completing his undergraduate degree at Duke University, Dr. Ellison received his medical degree from the University of Virginia. He completed his residency training in Family Medicine at Halifax Hospital Medical Center, University of South Florida, where he served as chief resident. Dr. Ellison is board certified in Family Medicine and is a diplomate of the American Academy of Family Physicians. He has attended the Advanced Leadership Program at the University of North Carolina at Chapel Hill and Harvard’s Advanced Management Program.

  • ALBERT BOURLA

    Pfizer

    Read Bio ⟶

    ALBERT BOURLA

    As Chairman and Chief Executive Officer, Albert Bourla leads Pfizer in its purpose: breakthroughs that change patients’ lives, with a focus on driving the scientific and commercial innovation needed to have a transformational impact on human health.

    During his more than 25 years at Pfizer, Albert has built a diverse and successful career, holding a number of senior global positions across a range of markets and disciplines. Prior to taking the reins as CEO in January 2019, Albert served as the Pfizer’s Chief Operating Officer (COO) beginning in January 2018, responsible for overseeing the Company’s commercial strategy, manufacturing, and global product development functions.

    Previously, from February 2016 to December 2017, Albert served as Group President of Pfizer Innovative Health, which comprised the Consumer Healthcare, Inflammation & Immunology, Internal Medicine, Oncology, Rare Disease and Vaccines business groups. In addition, he created the Patient and Health Impact Group, dedicated to developing solutions for increasing patient access, demonstrating the value of Pfizer’s medicines, and ensuring broader business model innovation.

    From January 2014 to January 2016, Albert served as Group President of Pfizer’s Global Vaccines, Oncology, and Consumer Healthcare business, where he was instrumental in building a strong and competitive position in Oncology and expanding the Company’s leadership in Vaccines.

    Albert was President and General Manager of Pfizer’s Established Products business from 2010-2013, leading the development and implementation of strategies and tactics related to Pfizer’s off-patent portfolio, (including legacy brands and generics.

    He began his Pfizer career in 1993 in the Animal Health Division as Technical Director of Greece. He held positions of increasing responsibility within Animal Health across Europe, before moving to Pfizer’s New York Global Headquarters in 2001. From there, Albert went on to assume a succession of leadership roles within the Animal Health Division, including US Group Marketing Director (2001-2004), Vice President of Business Development and New Products Marketing (2004-2006), and Area President of Animal Health Europe, Africa and the Middle East (2006-2009). In 2009, he assumed additional responsibilities for the Asia and Pacific regions.

    Albert is a Doctor of Veterinary Medicine and holds a Ph.D. in the Biotechnology of Reproduction from the Veterinary School of Aristotle University. In 2020, he was ranked as America’s top CEO in the Pharmaceuticals sector by Institutional Investor magazine. He is on the executive committee of The Partnership for New York City, a director on multiple boards – Pfizer, Inc., The Pfizer Foundation, PhRMA, and Catalyst – and a Trustee of the United States Council for International Business. In addition, Albert is a member of the Business Roundtable and the Business Council.

  • JUDY FAULKNER

    Epic

    Read Bio ⟶

    JUDY FAULKNER

    The developer of a comprehensive, patient-centric electronic medical record (EMR) system and founder of Epic Systems Corporation, Judith Faulkner is recognized for her scientific and technological leadership. Her vision for health care technology is both comprehensive and simple: provide the relevant medical information when it's needed, do what's best for the patient, and help clinicians collaborate. Her innovative health information technology infrastructure allows for the implementation of workflow steps, clinical guidelines, and best-practice alerts tailored to each clinician's role in patient care while on the patient end providing information regarding prescriptions, appointments, communication with the care team, and prevention/treatment reminders.

    Epic EMR systems do away with traditional paper files and provide a single, shared patient record which can be accessed by clinical staff across all manner of health care services and, with proper consent, across different health care organizations. Given the complexity and magnitude of medical data that may be included, the technological challenge has been to develop this comprehensive infrastructure for diverse health care settings while scaling to millions of records and thousands of concurrent users who all require rapid response times.

    Independent studies have documented the positive impact of Epic technologies on the quality of clinical care and the software has led to improvements in medical research. To date, 240 health care organizations use Epic technologies to provide medical care to approximately 118 million people. This includes fourteen Wisconsin organizations that increasingly serve as the early adopters of the latest advances in Epic's health technologies.

    Faulkner has led Epic strategically and operationally to create state-of-the-art technologies that improve the quality, safety, and efficiency of health care across Wisconsin, the United States, and, increasingly, the world.

  • JULIE SUNDERLAND

    Biomatics Capital

    Read Bio ⟶

    JULIE SUNDERLAND

    Prior to co-founding Biomatics Capital Partners in 2016, Ms. Sunderland was director of Program Related Investments for the Bill & Melinda Gates Foundation. She led the foundation’s $1.5 billion strategic investment pool, which focused on global health, global development and education. She funded 50 investments, including 30 in health care, and built a team of 10 investment professionals.

    Ms. Sunderland also chaired Bill & Melinda Gates Foundation’s investment committee, which reviews all program-related investments. Prior to that role, she advised foundations, development finance institutions and governments on venture capital, SME financing and technical assistance programs.Ms. Sunderland holds a B.A. from Harvard University, an MBA from Wharton Business School and an M.A. from Johns Hopkins School of Advanced International Studies.

    Ms. Sunderland sits on the Board of Directors for several of Biomatics’ portfolio companies including Aledade, BlackThorn, eGenesis and Verana.

  • JESSICA L. MEGA, M.D., M.P.H.

    Verily Life Sciences

    Read Bio ⟶

    JESSICA L. MEGA, M.D., M.P.H.

    Jessica L. Mega, M.D., M.P.H., is the Chief Medical Officer at Verily Life Sciences. As CMO, Mega’s focus is on translating scientific insights and technological innovations into partnerships and programs that improve patient outcomes. She oversees all of Verily’s clinical research efforts, including the Baseline Study.

  • HAL BARRON

    GSK

    Read Bio ⟶

    HAL BARRON

    Hal joined GSK in January 2018 as Chief Scientific Officer and President, R&D, responsible for all research and development of our pipeline molecules as well as life-cycle management of the approved medicines. He is an Executive Director of the GSK Board and a member of the Corporate Executive Team.

    His previous role was President, R&D at Calico (California Life Company). Prior to this, Hal was Executive Vice President, Head of Global Product Development, and Chief Medical Officer of Roche, responsible for all the products in the combined portfolio of Roche and Genentech. At Genentech, he was Senior Vice President of Development and Chief Medical Officer.

    Hal is an Associate Adjunct Professor, Epidemiology & Biostatistics, University of California, San Francisco. He is a Non-Executive Board Director of GRAIL, Inc, an early cancer detection healthcare company and a member of the Advisory Board of Verily Life Sciences LLC, a subsidiary of Alphabet, Inc. Hal was a Non-Executive Director and Chair of the Science & Technology Committee at Juno Therapeutics, Inc until March 2018, when it was acquired by Celgene Corporation.

    He holds a Bachelor of Science degree in Physics from Washington University in St Louis and a medical degree from Yale University. He completed his training in Cardiology and Internal Medicine at the University of California, San Francisco.

    Hal has been issued several patents for his work in thrombosis and angiogenesis and has published more than 90 papers in peer-reviewed scientific journals.

  • SCOTT GOTTLIEB

    Fmr. U.S. Food and Drug Administration

    Read Bio ⟶

    SCOTT GOTTLIEB

    Scott Gottlieb, MD is a physician and served as the 23rd Commissioner of the U.S. Food and Drug Administration. Dr. Gottlieb’s work focuses on advancing public health through developing and implementing innovative approaches to improving medical outcomes, reshaping healthcare delivery, and expanding consumer choice and safety.

    Dr. Gottlieb is an aggressive advocate for advancing the health of patients, promoting healthcare access, and driving innovation. The agency’s historic and prolific advances in new policy distinguished his tenure as the FDA’s commissioner, in addition to a record-setting number of approvals of novel drugs, medical devices, and generic medicines.

    Under his leadership, the FDA advanced new frameworks for the modern and safe and effective oversight of gene therapies, cell based regenerative medicines, targeted drugs, and digital health devices. The agency implemented new reforms to standardize drug reviews and make historic improvements of post market data collection and the use of real world evidence. He promoted policies to reduce death and disease from tobacco, improve food innovation and safety, and aggressively confront addiction crises.

    Previously, Dr. Gottlieb served as the FDA’s Deputy Commissioner for Medical and Scientific Affairs and before that, as a Senior Adviser to the Administrator of the Centers for Medicare and Medicaid Services, where he helped advance policies to improve healthcare quality and promote the effective use of new medical technologies. A healthcare futurist, he works as a venture capitalist and has been a founder and board member to companies that have developed new medicines and advance the delivery of healthcare.

    Dr. Gottlieb is widely published in leading medical journals and periodicals, including The Wall Street Journal, The New York Times, and The Washington Post. He has held editorial positions on the British Medical Journal and the Journal of the American Medical Association. Fortune Magazine recognized him as one of the “World’s 50 Greatest Leaders” in 2018 and again in 2019. Modern Healthcare named Dr. Gottlieb as one of the “Most Influential Physician Executive and Leaders” in its annual survey of 50 physician executives, and Time magazine named Gottlieb one of its “50 People Transforming Healthcare in 2018.”

    Dr. Gottlieb was a practicing hospitalist and a Clinical Assistant Professor at the New York University School of Medicine. He is an elected member of the National Academy of Medicine and a Resident Fellow at the American Enterprise Institute in Washington, DC.

  • ARIF NATHOO

    Komodo Health

    Read Bio ⟶

    ARIF NATHOO

    Arif Nathoo, M.D., is co-founder & chief executive officer at Komodo Health where he oversees data sciences, engineering, and product development initiatives for the company. He has spent the past 15 years in healthcare and life sciences leadership roles. Before Komodo Health, Arif was a leader in McKinsey’s Healthcare practice where he was responsible for helping enterprise healthcare address issues in corporate strategy, finance, sales and marketing, and organization building. He co-led McKinsey’s Medical Affairs Practice, which created analytic products and services to improve non-promotional engagement between industry and providers.

    He has conducted research in novel instructional technologies and medical devices, with multiple publications in peer-reviewed journals. Arif graduated magna cum laude with Highest Honors from Harvard University with an A.M. in molecular and cellular biology, an M.D. from Harvard Medical School, and M.P.A. in health policy from Harvard Kennedy School.

  • JOHN C. REED

    Sanofi

    Read Bio ⟶

    JOHN C. REED

    John Reed holds a B.A. in chemistry from the University of Virginia, Charlottesville and an M.D. and Ph.D. (Immunology) from the University of Pennsylvania School of Medicine.

    He began his academic career as a member of the faculty at the University of Pennsylvania in 1988, following a post-doctoral fellowship in Molecular Biology at the Wistar Institute and a residency in Pathology & Laboratory Medicine at the Hospital of the University of Pennsylvania. John Reed subsequently held faculty appointments at several universities including the University of California, the University of Florida and ETH-Zurich.

    In 1992, he joined the Sanford-Burnham Medical Research Institute in La Jolla, California, one of the largest independent non-profit biomedical research institutes in the United States. From 2002 to 2013, he served as CEO of the Institute. During his tenure, John Reed ran a highly productive laboratory that generated more than 900 research publications and over 130 patents, was awarded more than 100 research grants, and trained over 100 post-doctoral fellows. He is a Fellow of the American Association for the Advancement of Science (AAAS) and the recipient of numerous honors and awards for his accomplishments in biomedical research.

    John Reed has served on multiple editorial boards of research journals, and was scientific founder or co-founder of four biotechnology companies. He has served on the Board of Directors for five publicly traded biopharmaceutical and biotechnology companies and on the governing boards for various non-profit biomedical research organizations.

    From 2013 to 2018, John Reed was Global Head of Roche Pharmaceutical Research & Early Development, based at company headquarters in Basel, Switzerland. He was responsible for research through Phase IIb development for all therapeutic areas, overseeing R&D activities across 7 global sites.

    He assumed his current position as Executive Vice President, Global Head of Research & Development for Sanofi in July 2018.

  • TOM POLEN

    BD (Becton, Dickinson and Company)

    Read Bio ⟶

    TOM POLEN

    Tom Polen serves as chief executive officer and president of BD (Becton, Dickinson and Company), a global medical technology company headquartered in Franklin Lakes, New Jersey. He also leads the BD Executive Leadership Team.

    Polen joined BD in 1999, after growing an early phase start-up that was subsequently purchased by BD. From 1999 to 2004, he held a variety of sales and marketing positions with increasing responsibility, in BD Biosciences and BD Diagnostics Systems.

    In 2004, Polen joined Baxter Healthcare, where he led the pharmaceutical manufacturing and services business before assuming the role of vice president of Strategic Marketing. He was later promoted to general manager of Baxter’s Injectable Pharmaceuticals business. During his tenure at Baxter, Polen was named among Chicago’s top 40 leaders under 40, by Crain’s Chicago Business.

    In 2009, Polen rejoined BD as president of BD Preanalytical Systems. He assumed the role of president of BD Diagnostics Systems from 2010 to 2013, and later served as group president, responsible for BD Medical Surgical Systems and BD Pharmaceutical Systems. In 2014, Polen was named segment president, BD Medical, where he led the $12 billion acquisition of CareFusion in 2015, the company’s expansion into informatics and digital health solutions and the $24 billion acquisition of C. R. Bard, Inc. in 2017. Following the Bard acquisition, Polen was named president and chief operating officer in 2017 where he was responsible for the company’s three business segments – Medical, Life Sciences and Interventional, as well as Research and Development, Innovation, Operations and the commercial organization of the company’s Americas Region.

    Polen is an active benefactor and volunteer for the Children’s Tumor Foundation, as well as a number of national and local associations committed to helping patients with breast cancer. He earned his bachelor’s degree from the Salisbury University of Maryland and a master’s degree in business administration from Johns Hopkins University.

    About BD BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company develops innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its 65,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. BD helps customers enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. bd.com

  • ERIC TOPOL

    Scripps Research Translational Institute

    Read Bio ⟶

    ERIC TOPOL

    Eric Topol is the Founder and Director of the Scripps Research Translational Institute, Professor, Molecular Medicine, and Executive Vice-President of Scripps Research. As a researcher, he has published over 1,200 peer-reviewed articles, with more than 270,000 citations, elected to the National Academy of Medicine, and is one of the top 10 most cited researchers in medicine. His principal scientific focus has been on the genomic and digital tools to individualize medicine.

    In 2016, Topol was awarded a $207 million grant from the NIH to lead a significant part of the Precision Medicine (All of Us) Initiative, a prospective research program enrolling 1 million participants in the US. This is in addition to his role as principal investigator for a flagship $35M NIH grant to promote innovation in medicine. He has been voted as the #1 most influential physician leader in the United States in a national poll conducted by Modern Healthcare. Besides editing several textbooks, he has published 3 bestseller books on the future of medicine: The Creative Destruction of Medicine, The Patient Will See You Now, and Deep Medicine: How Artificial Intelligence Can Make Healthcare Human Again. Topol was commissioned by the UK 2018-2019 to lead planning for the National Health Service’s integration of AI and new technologies.

EVENT
VIDEOS

  • design element, an overlay

    The path forward for the health care industry at a time of unprecedented challenges

    Relive some of the biggest moments from the Healthy Returns Virtual Summit

    Open Video
  • design element, an overlay

    The Best of Healthy Returns

    How innovators and investors are working with patients and providers to develop dynamic new solutions and create healthy returns.

    Open Video
  • design element, an overlay

    Healthy Returns

    Top health care investors, CEOs and technologists explore the innovations that will drive better outcomes, financially and clinically.

    Open Video

EVENT VIDEOS

  • The path forward for the health care industry at a time of unprecedented challenges

    Relive some of the biggest moments from the Healthy Returns Virtual Summit

    Open Video
  • The Best of Healthy Returns

    How innovators and investors are working with patients and providers to develop dynamic new solutions and create healthy returns.

    Open Video
  • Healthy Returns

    Top health care investors, CEOs and technologists explore the innovations that will drive better outcomes, financially and clinically.

    Open Video

COMPANIES IN ATTENDANCE

  • Allergan
  • American Heart Association
  • CityMD
  • FedEx
  • Google
  • Memorial Sloan Kettering Cancer Center
  • PWC
  • RWJBarnabas Health